Efficacy and safety of scalp acupuncture for poststroke depression: A meta-analysis and systematic review.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
04 Aug 2023
04 Aug 2023
Historique:
medline:
7
8
2023
pubmed:
6
8
2023
entrez:
6
8
2023
Statut:
ppublish
Résumé
Poststroke depression (PSD) is a common clinical poststroke complication that adversely affects cognitive and physical function rehabilitation. Scalp acupuncture (SA) can significantly improve somatic dysfunction and emotional disorder in stroke patients. This meta-analysis aims to evaluate the effectiveness and safety of SA in the treatment of PSD. We conducted a comprehensive search of multiple electronic databases, including PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Internet, China Science and Technology Journal Database, Wan Fang Data Knowledge Service Platform, and China Biology Medicine databases until December 20, 2022, to identify randomized controlled trials investigating the efficacy of SA in the treatment of PSD. Two independent researchers screened the literature, extracted data, and assessed the risk of bias in the included studies based on the inclusion and exclusion criteria. We performed a meta-analysis of the eligible literature using RevMan 5.4.1 and Stata 15.0 software. This study comprised a total of 14 randomized controlled trials, 10 of which used SA and 4 of which used SA in combination with electroacupuncture therapy. The results of the meta-analysis revealed that the effective rate of the SA group was significantly higher than that of the Western medicine group (relative risk = 1.09, 95% confidence interval (CI) [1.02, 1.16], P = .008). Moreover, compared to the Western medicine group, the SA group demonstrated significant improvements in Hamilton depression scale scores (mean difference = -2.29, 95% CI [-3.88, -0.70], P = .005) and neurological function deficit scores (mean difference = -3.06, 95% CI [-5.91, -0.21], P = .04). Additionally, the SA group has a lower incidence of adverse events than the western medicine group (relative risk = 0.12, 95% CI [0.05, 0.29], P < .00001). SA has superior efficacy and safety compared to Western medicine for PSD. These findings suggest that SA could be a promising alternative treatment for the assessed condition. Due to the limited number and quality of the included literature, the above conclusions must be confirmed by additional high-quality research.
Sections du résumé
BACKGROUND
BACKGROUND
Poststroke depression (PSD) is a common clinical poststroke complication that adversely affects cognitive and physical function rehabilitation. Scalp acupuncture (SA) can significantly improve somatic dysfunction and emotional disorder in stroke patients. This meta-analysis aims to evaluate the effectiveness and safety of SA in the treatment of PSD.
METHODS
METHODS
We conducted a comprehensive search of multiple electronic databases, including PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Internet, China Science and Technology Journal Database, Wan Fang Data Knowledge Service Platform, and China Biology Medicine databases until December 20, 2022, to identify randomized controlled trials investigating the efficacy of SA in the treatment of PSD. Two independent researchers screened the literature, extracted data, and assessed the risk of bias in the included studies based on the inclusion and exclusion criteria. We performed a meta-analysis of the eligible literature using RevMan 5.4.1 and Stata 15.0 software.
RESULTS
RESULTS
This study comprised a total of 14 randomized controlled trials, 10 of which used SA and 4 of which used SA in combination with electroacupuncture therapy. The results of the meta-analysis revealed that the effective rate of the SA group was significantly higher than that of the Western medicine group (relative risk = 1.09, 95% confidence interval (CI) [1.02, 1.16], P = .008). Moreover, compared to the Western medicine group, the SA group demonstrated significant improvements in Hamilton depression scale scores (mean difference = -2.29, 95% CI [-3.88, -0.70], P = .005) and neurological function deficit scores (mean difference = -3.06, 95% CI [-5.91, -0.21], P = .04). Additionally, the SA group has a lower incidence of adverse events than the western medicine group (relative risk = 0.12, 95% CI [0.05, 0.29], P < .00001).
CONCLUSION
CONCLUSIONS
SA has superior efficacy and safety compared to Western medicine for PSD. These findings suggest that SA could be a promising alternative treatment for the assessed condition. Due to the limited number and quality of the included literature, the above conclusions must be confirmed by additional high-quality research.
Identifiants
pubmed: 37543780
doi: 10.1097/MD.0000000000034561
pii: 00005792-202308040-00023
pmc: PMC10403033
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e34561Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Turk J Phys Med Rehabil. 2021 Sep 01;67(3):365-369
pubmed: 34870125
J Clin Psychiatry. 2016 Mar;77(3):e319
pubmed: 27046319
Brain Res Bull. 2021 Mar;168:74-88
pubmed: 33359639
Vascul Pharmacol. 2016 Dec;87:14-22
pubmed: 27765537
Psychol Res Behav Manag. 2022 Jul 07;15:1689-1706
pubmed: 35832139
Chin Med J (Engl). 2019 Sep 20;132(18):2206-2212
pubmed: 31436596
Front Neurosci. 2023 Mar 21;17:1146946
pubmed: 37025378
Zhen Ci Yan Jiu. 2016 Dec 25;41(6):528-34
pubmed: 29071896
Curr Neuropharmacol. 2022;20(4):738-750
pubmed: 35168522
Neurology. 2005 Feb 8;64(3):428-33
pubmed: 15699370
J Tradit Chin Med. 2017 Apr;37(2):171-8
pubmed: 29960288
Am J Psychiatry. 2016 Mar 1;173(3):221-31
pubmed: 26684921
Pharmacol Ther. 2018 Apr;184:131-144
pubmed: 29128343
Anesthesiology. 2014 Feb;120(2):482-503
pubmed: 24322588
Zhongguo Zhen Jiu. 2016 Jun 12;36(6):663-667
pubmed: 29231468
Zhongguo Zhen Jiu. 2023 Jan 1;43(1):19-22
pubmed: 36633234
FASEB J. 2020 Oct;34(10):13376-13395
pubmed: 32812265
Neurosci Lett. 2016 Feb 26;615:66-71
pubmed: 26773866
Panminerva Med. 2012 Sep;54(3):161-70
pubmed: 22801433
Zhongguo Zhen Jiu. 2018 Nov 12;38(11):1141-4
pubmed: 30672192
J Stroke Cerebrovasc Dis. 2022 Feb;31(2):106225
pubmed: 34837758
Transl Psychiatry. 2020 Sep 30;10(1):334
pubmed: 32999279
Zhongguo Zhen Jiu. 2022 Nov 12;42(11):1216-20
pubmed: 36397217
Stroke. 2017 Feb;48(2):e30-e43
pubmed: 27932603
Front Psychiatry. 2019 Jan 23;9:761
pubmed: 30728786